Stocktoria
KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · IPO 2025-03-06
KESTRA MEDICAL TECHNOLOGIES, LTD. financials (annual)
Bars are annual figures from 2024 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | $95.1M | $59.8M | $27.8M |
| Gross profit | $48.9M | $24.2M | $362,000 |
| R&D expense | $19.5M | $15.7M | $15.5M |
| SG&A expense | $164.1M | $114.9M | $69.9M |
| Operating income | -$134.7M | -$106.4M | -$85.1M |
| Income tax | $294,000 | $135,000 | $24,000 |
| Net income | -$131.6M | -$113.8M | -$94.1M |
| EPS (diluted) | $-2.43 | $-5.13 | $-5.07 |
| Operating cash flow | -$81.7M | -$77.6M | -$72.2M |
| Free cash flow | -$116.6M | -$100.5M | -$84.5M |
| Cash & equivalents | $99.7M | $237.6M | $8.2M |
| Total assets | $358.5M | $295.7M | $45.9M |
| Total liabilities | $98.8M | $90.3M | $78.2M |
| Shareholders' equity | $259.7M | $205.4M | -$209.4M |
Growth · year-over-year · Revenue CAGR 84.9%
| Metric | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue growth | +59.0% | +115.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-04-30. Facts plus Stocktoria's own computed scores — not investment advice.